Topic

FDA Approval

NDA, BLA, ANDA, 505(b)(2), label language, review packages, and approval-pathway interpretation.

4 articles·Lives underApprovals Policy·Last updated 2026-05-13

Biosimilars· May 13, 2026 · 4 min read

How to read FDA biosimilar interchangeability without over-reading it

Interchangeability is a real FDA designation, but it is not a commercial launch plan. Here is what the Purple Book status does, what state substitution controls, and...

By Ran Chen#Biosimilars #Interchangeability #FDA Approval

Approvals· May 10, 2026 · 4 min read

Orange Book vs Purple Book: the launch-team read that prevents bad assumptions

Orange Book and Purple Book answer different regulatory questions. Mixing them up creates bad generic, biosimilar, exclusivity, and substitution assumptions.

By Ran Chen#Orange Book #Purple Book #FDA Approval

Pipeline· May 7, 2026 · 4 min read

Accelerated approval creates commercial risk even before confirmatory failure

Accelerated approval can speed access, but commercial teams still need a plan for confirmatory trials, label uncertainty, payer skepticism, and withdrawal risk.

By Ran Chen#Accelerated Approval #FDA Approval #Clinical Evidence

Generics· May 6, 2026 · 3 min read

Generic entry, ANDA, and 505(b)(2): the commercial difference

ANDA and 505(b)(2) pathways answer different commercial problems. Launch teams should separate therapeutic equivalence, reliance strategy, exclusivity, and payer...

By Ran Chen#Generics #505(b)(2)#Orange Book